022 82 44 44

Advanced analysis for effective cancer treatment management and monitoring

The continuous and rapid evolution of the molecular profile of cancer during treatment leads to tumor heterogeneity, giving the cancer significant survival advantages. Traditional procedures for assessing cancer status and treatment response usually take several months before it becomes clear whether the disease is progressing or if the treatment is effective. However, answers to these questions are needed as early as possible to adjust the treatment strategy in a timely manner.

Cancertrack – a minimally invasive diagnostic test designed for highly accurate, specific, and reliable disease monitoring, including the detection of recurrences and changes or mutations in the tumor’s molecular profile
Based on a safe blood test

Cancertrack provides real-time vital information that helps doctors make timely, clinically informed decisions (assessment of the disease status and severity, early detection of recurrence, treatment response, and molecular markers of drug resistance).

For professional use only
Developed, validated, and certified by Datar Cancer Genetics

Opportunities

Significantly higher information content compared to invasive biopsy
Unique, exceptional ability to detect minimal tumor activity
Dynamic analysis of the cancer's molecular profile
Assessment of all active tumor sites (overcoming tumor heterogeneity issues)
Information on mutant allele frequency and molecular residual disease
Details on acquired resistance mutations
Simplified report with recommendations for approved therapies and genomic markers
Disease/recurrence/tumor characteristic monitoring at any frequency (without the risks and consequences of radiation from scanning, hospitalization, anesthesia, or painful surgical biopsies)
Predictive indicator of therapeutic inefficacy before clinical/radiological disease progression
Real-time adjustment of treatments based on test results
Extensive/Wide coverage of biomarkers recommended by NCCN
Circulating tumor cells (CTCs) analysis
Detection limit: 0.1% mutant allele frequency

Advanced Technology

Cancertrack profiles the molecular characteristics of circulating tumor analytes (DNA, RNA, and tumor cells), including:

single nucleotide variants (SNVs)
short insertions and deletions (InDels)
copy number alterations (CNAs)
fusions/rearrangements
and circulating tumor cell counts

Clinical Effectiveness

Cancertrack has been clinically validated in accordance with strict international medical standards. The sensitivity and specificity of the test are 94.72% and 97.88%, respectively.

Indications

Patients diagnosed with cancer (for molecular profiling and baseline measurement of cell-free tumor DNA before starting therapy)
Patients undergoing treatment
Patients with an inadequate/unsatisfactory response to "standard therapy"
For early detection of recurrence
For active surveillance and monitoring of patients in remission
For monitoring “invisible” metastases and tumors

Decided to take the Cancertrack!

Book your first consultation with a doctor

The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Datar Cancer Genetics

Book a consultation

Where can I get tested?

Chisinau

21 N. Теstemițanu, street
Monday – Tuesday, 07:30 - 14:30 I Wednesday, 07:30 - 09:00

Laboratory Report

The test results provided in the laboratory report are intended for professional use only by qualified specialists, considering the
capabilities/limitations/characteristics of the test, the patient's current health status, clinical history, and diagnostic data.

VIEW SAMPLE REPORTS

Cancertrack